Autophagy/Apoptosis Balance in Placental Vascular Pathologies
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · Jan 15, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Autophagy/Apoptosis Balance in Placental Vascular Pathologies," is studying how certain cellular processes in the placenta may contribute to pregnancy complications like pre-eclampsia and growth issues in the baby. Scientists are particularly interested in understanding how the balance between cell survival and cell death is affected during these complications. By examining these processes, the researchers hope to find new ways to identify and manage risks for mothers and their babies during pregnancy.
To participate in this trial, women must be pregnant and experiencing complications related to the placenta, such as pre-eclampsia or reduced growth of the baby, and must be delivering at Nîmes University Hospital. Participants should be able to provide informed consent and have health insurance. Women with multiple pregnancies or existing health conditions, like high blood pressure before pregnancy, are not eligible. While the trial is not yet recruiting, those who qualify can expect to contribute to important research that could lead to better understanding and prevention of serious pregnancy complications.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant women developing a placental vascular complication (preeclampsia and/or intrauterine growth retardation), hospitalized and delivering at Nîmes University Hospital.
- • Pregnant woman with free and informed consent.
- • Pregnant woman affiliated with and/or benefiting from a health insurance scheme.
- Exclusion criteria:
- • Multiple pregnancy.
- • Presence of hypertension and/or proteinuria prior to pregnancy.
- • Participant in an interventional drug study.
- • Persons in a period of exclusion determined by another study.
- • Persons under court protection, guardianship or curatorship.
- • Persons unable to give consent.
- • Persons for whom it is impossible to give informed information.
About Centre Hospitalier Universitaire De Nīmes
The Centre Hospitalier Universitaire de Nîmes (CHU Nîmes) is a leading academic medical center located in Nîmes, France, dedicated to advancing healthcare through innovative clinical research and patient care. As a prominent sponsor of clinical trials, CHU Nîmes collaborates with a multidisciplinary team of healthcare professionals and researchers to conduct rigorous studies aimed at improving treatment outcomes and enhancing medical knowledge across various specialties. With a strong commitment to ethical standards and patient safety, CHU Nîmes fosters a research environment that encourages scientific excellence and contributes to the development of new therapies and healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nîmes, , France
Patients applied
Trial Officials
Marie PORTES, Dr.
Principal Investigator
Nîmes University Hospital
Mathieu FORTIER, Dr.
Principal Investigator
Nîmes University Hospital
Jean-Christophe GRIS, Pr.
Principal Investigator
Nîmes University Hospital
Eve MOUSTY, Dr.
Principal Investigator
Nîmes University Hospital
Vincent LETOUZEY, Dr.
Principal Investigator
Nîmes University Hospital
Stéphanie HUBERLANT, Dr.
Principal Investigator
Nîmes University Hospital
Chloé BOURGUIGNON, Dr.
Principal Investigator
Nîmes University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported